Verzenio (abemaciclib)

pCPA File Number: 22879
Negotiation Status:
Concluded with an LOI
Indication(s):
​In combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of disease recurrence based on clinicopathological features
Sponsor/Manufacturer:
Eli Lilly Canada Inc.
CDA-AMC Project Number:
PC0345-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: